Menarini has launched ‘Firing Too Quickly’ – a UK campaign designed to raise public and healthcare provider awareness of premature ejaculation and its treatment. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/menarini_launches_male_sexual_health_campaign_1001378The UK's Medicines and Healthcare products Regulatory Agency's latest ‘drug safety update’ (February) flags the increased cardiovascular monitoring required when patients are given their first dose of Novartis' oral multiple sclerosis drug Gilenya. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/novartis_awaits_gilenya_ema_review_975681Hormone replacement therapies should carry a stronger warning about the risk of causing potentially fatal asthma exacerbations in susceptible women, says the author of a major study presented at the European Respiratory Society congress in Amsterdam. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/hrt_products_need_stronger_asthma_warning_980334Eisai has officially launched Halaven in the UK, just a week after production of the novel breast cancer treatment started at the company’s £600 million manufacturing facility at Hatfield, Hertfordshire. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/eisai_rolls_out_halaven_in_uk_980982A raft of data on licensed and investigational multiple sclerosis treatments will be unveiled by Novartis at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, which opens today (October 10) in Lyon, France. - News - PharmaTimes
by Ian Mason in Lyon
www.pharmatimes.com/news/upbeat_novartis_showcases_ms_portfolio_at_ectrims_976475There were brickbats a-plenty for big pharma at the European Congress of Clinical Microbiology and Infectious Diseases meeting in Milan, Italy, with drugmakers being criticised for their poor performance in the antibiotics R&D field. - News - PharmaTimes
by By Ian Mason in Milan
www.pharmatimes.com/news/spotlight_on_superbugs_at_eccmid_meeting_981089New research has flagged the value of early aggressive antidepressant treatment in adolescents who have failed to respond to SSRIs. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/treatment-switch_trumps_resistant-depression_in_teens_983221Two important milestones for Raptiva (efalizumab) – Merck Serono’s biological therapy for psoriasis – were reached this weekend. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/postmarketing_data_highlight_efficacy_of_raptiva_986983InterMune, which is in the process of being acquired by Roche for $8.3 billion, says that data over 72 weeks provides further evidence of a durable pirfenidone treatment benefit on multiple measures of idiopathic pulmonary fibrosis including reducing the risk of mortality. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/intermune_boosted_by_pirfenidone_data_1002439Sanofi Pasteur is poised to produce the first validation batches of their dengue vaccine at the company’s state-of-the-art production centre near Lyon, France. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/sanofi_starts_dengue_vaccine_production_for_2015_launch_1005375
